Plus Therapeutics’ (PSTV) Buy Rating Reaffirmed at HC Wainwright
Plus Therapeutics (NASDAQ:PSTV – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $8.00 price objective on the stock. Separately, Ascendiant Capital Markets dropped their price target on Plus Therapeutics from $21.00 to $20.00 […]
More Stories
Elios Financial Group Inc. Takes Position in Walmart Inc. (NYSE:WMT)
Elios Financial Group Inc. acquired a new position in Walmart Inc. (NYSE:WMT – Free Report) in the 3rd quarter, according...
Boston Scientific Co. (NYSE:BSX) Shares Sold by Quantbot Technologies LP
Quantbot Technologies LP reduced its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 0.8% in the...
Harvest Fund Management Co. Ltd Increases Stake in Illumina, Inc. (NASDAQ:ILMN)
Harvest Fund Management Co. Ltd increased its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 53.1% during...
Quantbot Technologies LP Purchases 277,245 Shares of Amphenol Co. (NYSE:APH)
Quantbot Technologies LP lifted its position in shares of Amphenol Co. (NYSE:APH – Free Report) by 231.5% in the 3rd...
Philip Morris International Inc. (NYSE:PM) Stake Lifted by Brooklyn Investment Group
Brooklyn Investment Group increased its position in shares of Philip Morris International Inc. (NYSE:PM – Free Report) by 182.4% during...
Principal Street Partners LLC Has $738,000 Stock Position in Generac Holdings Inc. (NYSE:GNRC)
Principal Street Partners LLC lowered its position in Generac Holdings Inc. (NYSE:GNRC – Free Report) by 2.0% in the third...